Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diatrizoic acid
Drug ID BADD_D00647
Description A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Indications and Usage Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium.
Marketing Status approved; vet_approved
ATC Code V08AA01
DrugBank ID DB00271
KEGG ID D02240
MeSH ID D003973
PubChem ID 2140
TTD Drug ID D0T9DT
NDC Product Code Not Available
UNII 5UVC90J1LK
Synonyms Diatrizoate | Benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo- | Hypaque | Diatrizoic Acid | Urothrast | Urotrast | Urogranoic Acid | Sodium Diatrizoate | Diatrizoate, Sodium | Diatrizoate Sodium | Sodium-Magnesium Diatrizoate | Diatrizoate, Sodium-Magnesium | Amidotrezoate | Amidotrizoate | Hypaque 50
Chemical Information
Molecular Formula C11H9I3N2O4
CAS Registry Number 117-96-4
SMILES CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anuria20.01.03.002--Not Available
Aphasia19.21.01.001; 17.02.03.001--
Apnoea22.02.01.001--
Application site pain08.02.01.004; 12.07.01.004--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Azotaemia20.01.01.001--Not Available
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blindness unilateral06.02.10.007; 17.17.01.016--Not Available
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.001--
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.009--Not Available
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.019--Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.12.03.003--Not Available
Circulatory collapse24.06.02.001--Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages